New and old prognostic factors in polycythemia vera.

被引：2
作者：
Passamonti F. [1 ]
机构：
[1] Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, Pavia
来源：
Current Hematologic Malignancy Reports | 2009年 / 4卷 / 1期
关键词：
Polycythemia Vera; Essential Thrombocythemia; Myeloproliferative Disorder; JAK2V617F Mutation; JAK2 Inhibitor;
D O I：
10.1007/s11899-009-0003-8
中图分类号：
学科分类号：
摘要：
Polycythemia vera is a chronic myeloproliferative disorder affecting people in the sixth decade of life. The disease is considered long-lasting; median survival exceeds 18 years. As thrombosis is the main complication during follow-up, scoring systems have focused on the risk of thrombosis. Age over 60 years and prior thrombosis are considered the standard risk factors for thrombosis and represent the state of the art for risk stratification in decision making regarding treatment. However, new disease-based risk factors-leukocytosis and the JAK2V617F mutation burden-seem to be emerging as indicators of prognosis in polycythemia vera. Leukocytosis, as a marker of disease proliferation, seems to have an impact on thrombosis, post-polycythemia vera myelofibrosis, leukemia, and survival. The role of the JAK2V617F mutation as a prognostic factor requires further validation, but it may have a dominant role in disease progression and in the activation of platelets and leukocytes.
引用
收藏
页码：19 / 24
页数：5
相关论文
共 131 条
  • [1] Passamonti F.(2004)Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 755-761
  • [2] Rumi E.(2003)Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia Haematologica 88 13-18
  • [3] Pungolino E.(2005)A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779-1790
  • [4] Passamonti F.(2008)Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood 111 1686-1689
  • [5] Malabarba L.(2007)JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459-468
  • [6] Orlandi E.(2007)Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood 109 2446-2452
  • [7] Kralovics R.(2008)A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood 111 3383-3387
  • [8] Passamonti F.(2007)Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation Br J Haematol 138 354-358
  • [9] Buser A.S.(1991)Life expectancy of patients with chronic nonleukemic myeloproliferative disorders Cancer 67 2658-2663
  • [10] Pietra D.(2003)Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy Hematol J 4 198-207
12345678910